CAJ | 학술논문

目的：评价CT引导下射频消融（RFA）治疗肺癌的疗效及安全性。方法回顾性分析2007年5月至2013年8月接受RFA治疗的33例肺癌患者的35个病灶的治疗情况。所有行RFA的患者术后每3个月随访，以评估疗效和不良反应。随访截止日期为2013年12月或肿瘤出现进展。结果有完整随访数据的32例肺癌患者的34个病灶消融后1年局部控制率为85．3%。平均1年无进展生存率75．0%，其中15例原发性肺癌的1年无进展生存率为80．0%，17例转移性肺癌为70．6%。总体的中位无进展生存期（mPFS）为（18．0±1．3）个月。不同的年龄、性别、肿瘤大小、病理类型、临床分期等均与患者预期mPFS无显著相关（P＞0．05）。 RFA的主要不良反应为疼痛、胸腔积液及气胸，未出现危及生命的严重并发症。结论对早期或是晚期肺癌，RFA都是一种安全有效的微创治疗。
목적：평개CT인도하사빈소융（RFA）치료폐암적료효급안전성。방법회고성분석2007년5월지2013년8월접수RFA치료적33례폐암환자적35개병조적치료정황。소유행RFA적환자술후매3개월수방，이평고료효화불량반응。수방절지일기위2013년12월혹종류출현진전。결과유완정수방수거적32례폐암환자적34개병조소융후1년국부공제솔위85．3%。평균1년무진전생존솔75．0%，기중15례원발성폐암적1년무진전생존솔위80．0%，17례전이성폐암위70．6%。총체적중위무진전생존기（mPFS）위（18．0±1．3）개월。불동적년령、성별、종류대소、병리류형、림상분기등균여환자예기mPFS무현저상관（P＞0．05）。 RFA적주요불량반응위동통、흉강적액급기흉，미출현위급생명적엄중병발증。결론대조기혹시만기폐암，RFA도시일충안전유효적미창치료。
Objective To investigate the efficacy and safety of CT-guided radiofrequency ablation (RFA) in treating lung tumors. Methods A total of 33 patients with lung cancer (35 lesions in total), who were admitted to authors’ hospital during the period from May 2007 to August 2013 to receive treatment, were enrolled in this study. RFA was carried out in all patients. After RFA the patients were followed up regularly (once every 3 months) to evaluate the therapeutic efficacy and the adverse reaction. The deadline for the following-up was November 2013, or to the time when tumor progression occurred. Results Of the total 34 lesions in 32 patients who had received RFA and had complete follow-up data, the one-year local control rate was 85.3%. The average one-year progression-free survival rate was 75.0%, among them 15 cases with primary lung cancer had a mean one-year progression-free survival rate of 80.0% and 17 cases with metastatic lung cancer had a mean one-year progression-free survival rate of 70.6%. The overall median progression-free survival (PFS) was(18.0±1.3) months. No obvious correlation existed between PFS and age, sex, tumor size, pathological type, clinical stage (P<0.05). The main adverse reactions of RFA were pain, hydrothorax and pneumothorax; no serious life-threatening complications occurred. Conclusion RFA is a safe, effective and minimally-invasive treatment for lung cancer, regardless of early stage or late stage of the tumor.